{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:11:32Z","timestamp":1788617492591,"version":"build-2803163510"},"reference-count":34,"publisher":"Akademiai Kiado Zrt.","issue":"35","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,8,30]]},"abstract":"\n Bevezet\u00e9s:<\/jats:italic>\n Az androg\u00e9n alopecia a hajveszt\u00e9ssel j\u00e1r\u00f3\n leggyakoribb k\u00f3rk\u00e9p, amely kr\u00f3nikus, progressz\u00edv lefoly\u00e1s\u00fa, \u00e9s jelent\u0151s\n pszichoszoci\u00e1lis terhet jelent a betegek sz\u00e1m\u00e1ra.\n C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n A\n k\u00f6zlem\u00e9ny c\u00e9lja az androg\u00e9n alopecia kezel\u00e9s\u00e9re vonatkoz\u00f3 nemzetk\u00f6zi ir\u00e1nyelvek\n \u00e9s szak\u00e9rt\u0151i konszenzusok \u00f6sszehasonl\u00edt\u00f3 elemz\u00e9se, valamint a klinikai\n gyakorlatban alkalmazhat\u00f3 \u00f6sszefoglal\u00e1sa.\n M\u00f3dszer:<\/jats:italic>\n Irodalomkutat\u00e1st v\u00e9gezt\u00fcnk a PubMed adatb\u00e1zisban 2015 \u00e9s 2025 k\u00f6z\u00f6tt publik\u00e1lt,\n angol nyelv\u0171 ir\u00e1nyelvek \u00e9s szak\u00e9rt\u0151i aj\u00e1nl\u00e1sok azonos\u00edt\u00e1s\u00e1ra. A bevont\n dokumentumokat narrat\u00edv m\u00f3don elemezt\u00fck, \u00e9s ter\u00e1pi\u00e1s szempont\u00fa \u00f6sszehasonl\u00edt\u00e1st\n v\u00e9gezt\u00fcnk.\n Eredm\u00e9nyek:<\/jats:italic>\n A klasszikus kezel\u00e9sek \u2013 mint a\n topik\u00e1lis minoxidil \u00e9s az 5-alfa-redukt\u00e1z-g\u00e1tl\u00f3k \u2013 tov\u00e1bbra is a ter\u00e1pia alapj\u00e1t\n k\u00e9pezik. Az \u00fajabb aj\u00e1nl\u00e1sok egyre nagyobb szerepet tulajdon\u00edtanak a kis d\u00f3zis\u00fa\n or\u00e1lis minoxidilnek \u00e9s a dutaszteridnek, ugyanakkor ezek meg\u00edt\u00e9l\u00e9se az egyes\n ir\u00e1nyelvek k\u00f6z\u00f6tt elt\u00e9r\u0151. A procedur\u00e1lis kezel\u00e9sek szerepe szint\u00e9n v\u00e1ltoz\u00f3,\n els\u0151sorban a korl\u00e1tozott evidenci\u00e1k miatt.\n K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n A\n k\u00fcl\u00f6nb\u00f6z\u0151 aj\u00e1nl\u00e1sok k\u00f6z\u00f6tti elt\u00e9r\u00e9sek h\u00e1tter\u00e9ben az evidenciaszintek k\u00fcl\u00f6nbs\u00e9ge\n \u00e9s az \u00faj ter\u00e1pi\u00e1k elt\u00e9r\u0151 meg\u00edt\u00e9l\u00e9se \u00e1ll. A klinikai gyakorlatban a betegre\n szabott, kombin\u00e1lt kezel\u00e9si strat\u00e9gia \u00e9s a rendszeres k\u00f6vet\u00e9s kiemelt\n jelent\u0151s\u00e9g\u0171. Az androg\u00e9n alopecia kezel\u00e9se gyorsan fejl\u0151d\u0151 ter\u00fclet, ahol a\n ter\u00e1pi\u00e1s d\u00f6nt\u00e9sek individualiz\u00e1lt megk\u00f6zel\u00edt\u00e9st ig\u00e9nyelnek. Orv Hetil. 2026;\n 167(35): 1385\u20131393.\n <\/jats:p>","DOI":"10.1556\/650.2026.33637","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:15:26Z","timestamp":1788614126000},"page":"1385-1393","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az androg\u00e9n alopecia korszer\u0171 kezel\u00e9se"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7084-073X","authenticated-orcid":true,"given":"Petra","family":"R\u00f3zsa","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Oktat\u00e1si K\u00f6zpont, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Kem\u00e9ny","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Oktat\u00e1si K\u00f6zpont, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"},{"name":"HUN-REN\u2013SZTE Dermatol\u00f3giai Kutat\u00f3csoport Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolland","family":"Gyulai","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Oktat\u00e1si K\u00f6zpont, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","unstructured":"MedlinePlus. Androgenetic alopecia. Available from:\n https:\/\/medlineplus.gov\/genetics\/condition\/androgenetic-alopecia\n [accessed: July 27, 2023]."},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Frith H, Jankowski GS. Psychosocial impact of androgenetic alopecia\n on men: a systematic review and meta-analysis. Psychol Health Med. 2024; 29:\n 822-842.\n https:\/\/doi.org\/10.1080\/13548506.2023.2242049","DOI":"10.1080\/13548506.2023.2242049"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Xiao Y, Zhang Y, Deng S, et al. Immune and non-immune interactions\n in the pathogenesis of androgenetic alopecia. Clin Rev Allergy Immunol. 2025;\n 68: 22. https:\/\/doi.org\/10.1007\/s12016-025-09034-5","DOI":"10.1007\/s12016-025-09034-5"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Norwood OT. Male pattern baldness. Classification and incidence.\n SouthMed J. 1975; 68: 1359-1365.\n https:\/\/doi.org\/10.1097\/00007611-197511000-00009","DOI":"10.1097\/00007611-197511000-00009"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Vujovic A, Del Marmol V. The female pattern hair loss: review of\n etiopathogenesis and diagnosis. Biomed Res Int. 2014; 2014: 767628.\n https:\/\/doi.org\/10.1155\/2014\/767628","DOI":"10.1155\/2014\/767628"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline\n for the treatment of androgenetic alopecia in women and in men - short version.\n J Eur Acad Dermatol Venereol. 2018; 32: 11-22.\n https:\/\/doi.org\/10.1111\/jdv.14624","DOI":"10.1111\/jdv.14624"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Manabe M, Tsuboi R, Itami S, et al. Guidelines for the diagnosis and\n treatment of male-pattern and female-pattern hair loss, 2017 version. J\n Dermatol. 2018; 45: 1031-1043.\n https:\/\/doi.org\/10.1111\/1346-8138.14470","DOI":"10.1111\/1346-8138.14470"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Alessandrini A, Starace M, D\u2019Ovidio R, et al. Androgenetic alopecia\n in women and men: Italian guidelines adapted from European Dermatology\n Forum\/European Academy of Dermatology and Venereology guidelines. G Ital\n Dermatol Venereol. 2020; 155: 622-631.\n https:\/\/doi.org\/10.23736\/S0392-0488.19.06399-5","DOI":"10.23736\/S0392-0488.19.06399-5"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Fernandez-Crehuet P, Garnacho G, et al.\n Recommendations on the clinical management of androgenetic alopecia: a consensus\n statement from the Spanish Hair Disorders Group of the Spanish Academy of\n Dermatology and Venererology (AEDV). [Recomendaciones sobre el manejo cl\u00ednico de\n la alopecia androg\u00e9nica: un documento de consenso del Grupo Espa\u00f1ol de\n Tricolog\u00eda de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda.] Acta\n Dermosifiliogr. 2024; 115: T347-T355. [Spanish]\n https:\/\/doi.org\/10.1016\/j.ad.2023.10.013","DOI":"10.1016\/j.ad.2023.10.013"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Landells I, Chow E, Gupta AK, et al. A Canadian consensus on\n androgenetic alopecia: approach and management. J Cutan Med Surg. 2025;\n 29(5_Suppl): 5S-14S.\n https:\/\/doi.org\/10.1177\/12034754251368849","DOI":"10.1177\/12034754251368849"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Shorter K, Farjo NP, Picksley SM, et al. Human hair follicles\n contain two forms of ATP-sensitive potassium channels, only one of which is\n sensitive to minoxidil. FASEB J. 2008; 22: 1725-1736.\n https:\/\/doi.org\/10.1096\/fj.07-099424","DOI":"10.1096\/fj.07-099424"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Li M, Marubayashi A, Nakaya Y, et al. Minoxidil-induced hair growth\n is mediated by adenosine in cultured dermal papilla cells: possible involvement\n of sulfonylurea receptor 2b as a target of minoxidil. J Invest Dermatol. 2001;\n 117: 1594-1600.\n https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01570.x","DOI":"10.1046\/j.0022-202x.2001.01570.x"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Davies GC, Thornton MJ, Jenner TJ, et al. Novel and established\n potassium channel openers stimulate hair growth in vitro: implications for their\n modes of action in hair follicles. J Invest Dermatol. 2005; 124: 686-694.\n https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23643.x","DOI":"10.1111\/j.0022-202X.2005.23643.x"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Akiska YM, Mirmirani P, Roseborough I, et al. Low-dose oral\n minoxidil initiation for patients with hair loss: an International Modified\n Delphi Consensus Statement. JAMA Dermatol. 2025; 161: 87-95.\n https:\/\/doi.org\/10.1001\/jamadermatol.2024.4593","DOI":"10.1001\/jamadermatol.2024.4593"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Penha MA, Miot HA, Kasprzak M, et al. Oral minoxidil vs topical\n minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA\n Dermatol. 2024; 160: 600-605.\n https:\/\/doi.org\/10.1001\/jamadermatol.2024.0284","DOI":"10.1001\/jamadermatol.2024.0284"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Dias FR, Yong SS, FitzGerald H, et al. Expanding the therapeutic\n landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual\n formulations. Front Pharmacol. 2026; 16: 1718208.\n https:\/\/doi.org\/10.3389\/fphar.2025.1718208","DOI":"10.3389\/fphar.2025.1718208"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Clissold SP, Heel RC. Topical minoxidil. A preliminary review of its\n pharmacodynamic properties and therapeutic efficacy in alopecia areata and\n alopecia androgenetica. Drugs 1987; 33: 107-122.\n https:\/\/doi.org\/10.2165\/00003495-198733020-00002","DOI":"10.2165\/00003495-198733020-00002"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Ahmed KM, Kozaa YA, Abuawwad MT, et al. Evaluating the efficacy and\n safety of combined microneedling therapy versus topical minoxidil in\n androgenetic alopecia: a systematic review and meta-analysis. Arch Dermatol Res.\n 2025; 317: 528.\n https:\/\/doi.org\/10.1007\/s00403-025-04032-1","DOI":"10.1007\/s00403-025-04032-1"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Olsen EA. Hair loss in women. N Eng J Med. 2025; 393: 1509-1520.\n https:\/\/doi.org\/10.1056\/NEJMcp2412146","DOI":"10.1056\/NEJMcp2412146"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety\n of topical finasteride spray solution for male androgenetic alopecia: a phase\n III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;\n 36: 286-294. Erratum: J Eur Acad Dermatol Venereol. 2023; 37: 452.\n https:\/\/doi.org\/10.1111\/jdv.17738","DOI":"10.1111\/jdv.17738"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Gupta AK, Talukder M, Keene SA, et al. Is the safety of finasteride\n correlated with its route of administration: topical versus oral? A\n pharmacovigilance study with data from the United States Food and Drug\n Administration Adverse Event Reporting System. Int J Dermatol. 2026; 65:\n 108-118. https:\/\/doi.org\/10.1111\/ijd.17957","DOI":"10.1111\/ijd.17957"},{"key":"R22","unstructured":"Food and Drug Administration. Propecia (finasteride), FDA\n prescribing information. Available from:\n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020788s028lbl.pdf\n [accessed: June, 2021]."},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Zhong X, Yang Y, Wei S, et al. Multidimensional assessment of\n adverse events of finasteride: a real-world pharmacovigilance analysis based on\n FDA adverse event reporting system (FAERS) from 2004 to April 2024. PLOS ONE\n 2025; 20: e0309849.\n https:\/\/doi.org\/10.1371\/journal.pone.0309849","DOI":"10.1371\/journal.pone.0309849"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Leliefeld HH, Debruyne FM, Reisman Y. The post-finasteride syndrome:\n possible etiological mechanisms and symptoms. Int J Impot Res. 2025; 37:\n 414-421. https:\/\/doi.org\/10.1038\/s41443-023-00759-5","DOI":"10.1038\/s41443-023-00759-5"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Asanad K, Sholklapper T, Samplaski MK, et al. Global online interest\n in finasteride sexual side effects. Int J Impot Res. 2024; 36: 408-413.\n https:\/\/doi.org\/10.1038\/s41443-022-00612-1","DOI":"10.1038\/s41443-022-00612-1"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Pompili M, Magistri C, Maddalena S, et al. Risk of depression\n associated with finasteride treatment. J Clin Psychopharmacol. 2021; 41:\n 304-309.\n https:\/\/doi.org\/10.1097\/JCP.0000000000001379","DOI":"10.1097\/JCP.0000000000001379"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality\n and psychological adverse events in patients treated with finasteride. JAMA\n Dermatology 2021; 157: 35-42.\n https:\/\/doi.org\/10.1001\/jamadermatol.2020.3385","DOI":"10.1001\/jamadermatol.2020.3385"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Basaria S, Jasuja R, Huang G, et al. Characteristics of men who\n report persistent sexual symptoms after finasteride use for hair loss. J Clin\n Endocrinol Metab. 2016; 101: 4669-4680.\n https:\/\/doi.org\/10.1210\/jc.2016-2726","DOI":"10.1210\/jc.2016-2726"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Chiappini S, Corkery JM, Guirguis A, et al. Signal detection of\n depression and suicidality associated with finasteride and dutasteride: updated\n pharmacovigilance evidence and recommendations for comprehensive psychiatric\n assessment. Brain Sci. 2026; 16: 394.\n https:\/\/doi.org\/10.3390\/brainsci16040394","DOI":"10.3390\/brainsci16040394"},{"key":"R30","unstructured":"Food and Drug Administration. Spironolactone and\n hydrochlorothiazide. Available from:\n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/012616s085lbl.pdf\n [accessed: Nov, 2025]."},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the\n management of acne vulgaris. J Am Acad Dermatol. 2024; 90: 1006.e1-1006.e30.\n Erratum: J Am Acad Dermatol. 2026; 95: 347.\n https:\/\/doi.org\/10.1016\/j.jaad.2023.12.017","DOI":"10.1016\/j.jaad.2023.12.017"},{"key":"R32","unstructured":"Food and Drug Administration. Bicalutamide. Available from:\n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/079089s000lbl.pdf\n [accessed: October 2017]."},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic\n alopecia: A review of the literature and proposed treatment protocol. Int J\n Womens Dermatol. 2018; 5: 46-51.\n https:\/\/doi.org\/10.1016\/j.ijwd.2018.08.004","DOI":"10.1016\/j.ijwd.2018.08.004"},{"key":"R34","unstructured":"Ke J, Guan H, Li S, et al. Erbium: YAG laser (2,940 nm) treatment\n stimulates hair growth through upregulating Wnt 10b and \u03b2-catenin expression in\n C57BL\/6 mice. Int J Clin Exp Med. 2015; 8: 20883-20889."}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/35\/article-p1385.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/35\/article-p1385.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/35\/article-p1385.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:15:33Z","timestamp":1788614133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/35\/article-p1385.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":34,"journal-issue":{"issue":"35"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33637","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}